Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

224
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
224
Anticholinesterase Agents: Poisoning and Treatment01:26

Anticholinesterase Agents: Poisoning and Treatment

927
Anticholinesterases, also known as cholinesterase inhibitors, work by blocking the breakdown of acetylcholine, leading to its accumulation in the synaptic cleft. This accumulation indirectly enhances both muscarinic and nicotinic actions. These agents are classified as reversible or irreversible based on their mechanism of action.     
Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is...
927
Antiepileptic Drugs: Glutamate Antagonists01:14

Antiepileptic Drugs: Glutamate Antagonists

435
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
435
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

1.6K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
1.6K
Acute Pyelonephritis II: Diagnostic Studies and Management01:28

Acute Pyelonephritis II: Diagnostic Studies and Management

19
Introduction:For diagnosing acute pyelonephritis, a comprehensive patient history is collected to identify symptoms such as dysuria, frequent or urgent urination, flank pain, or costovertebral angle (CVA) tenderness that may suggest a kidney infection.Physical ExaminationDuring the physical examination, CVA tenderness is assessed. This involves gentle percussion over the costovertebral angle, where tenderness often indicates a kidney infection.Diagnostic TestsUrinalysis: Used to identify white...
19
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

9
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
9

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Meningococcal prophylaxis in neurological diseases treated with complement inhibitors: an expert consensus for Germany, Austria, and Switzerland.

Therapeutic advances in neurological disorders·2026
Same author

Vestibular and Ocular Motor Phenotype in a Case of Paraneoplastic Autoimmune Kelch-Like Protein-11 Encephalitis.

Neurology(R) neuroimmunology & neuroinflammation·2026
Same author

Interpersonal Profiles in Social Anxiety Disorder: Different Settings, Different Outcomes?

Journal of clinical psychology·2026
Same author

Complement Inhibition for Acute Neuromyelitis Optica Spectrum Disorder Attacks: Insights From an International Case Series.

Neurology(R) neuroimmunology & neuroinflammation·2026
Same author

Fungal keratitis in Germany : Diagnostics, conservative and microsurgical treatment.

Die Ophthalmologie·2026
Same author

Association of treatment decision with personality, coping strategies and impulsivity in patients with multiple sclerosis.

Multiple sclerosis journal - experimental, translational and clinical·2026

Related Experiment Video

Updated: Jul 27, 2025

Author Spotlight: Evaluating the Adjuvant Efficacy and Safety of Angong Niuhuang Pill in Viral Encephalitis Treatment
08:36

Author Spotlight: Evaluating the Adjuvant Efficacy and Safety of Angong Niuhuang Pill in Viral Encephalitis Treatment

Published on: April 19, 2024

612

The three pillars in treating antibody-mediated encephalitis.

S Macher1, G Bsteh1, E Pataraia1

  • 1Department of Neurology, Medical University of Vienna, Vienna, Austria.

Wiener Klinische Wochenschrift
|June 6, 2023
PubMed
Summary

Rapid immunotherapy initiation is crucial for antibody-mediated encephalitis (AE). This review contrasts antiseizure, antipsychotic, and immunotherapy treatments for AE, emphasizing standardized care, especially in severe cases.

Keywords:
Antineuronal antibodiesAntipsychoticsAutoimmune encephalitisEpilepsyImmunotherapy

More Related Videos

High-throughput Flow Cytometry Cell-based Assay to Detect Antibodies to N-Methyl-D-aspartate Receptor or Dopamine-2 Receptor in Human Serum
10:19

High-throughput Flow Cytometry Cell-based Assay to Detect Antibodies to N-Methyl-D-aspartate Receptor or Dopamine-2 Receptor in Human Serum

Published on: November 23, 2013

16.4K
Hippocampal Neuronal Cultures to Detect and Study New Pathogenic Antibodies Involved in Autoimmune Encephalitis
08:20

Hippocampal Neuronal Cultures to Detect and Study New Pathogenic Antibodies Involved in Autoimmune Encephalitis

Published on: June 2, 2022

3.3K

Related Experiment Videos

Last Updated: Jul 27, 2025

Author Spotlight: Evaluating the Adjuvant Efficacy and Safety of Angong Niuhuang Pill in Viral Encephalitis Treatment
08:36

Author Spotlight: Evaluating the Adjuvant Efficacy and Safety of Angong Niuhuang Pill in Viral Encephalitis Treatment

Published on: April 19, 2024

612
High-throughput Flow Cytometry Cell-based Assay to Detect Antibodies to N-Methyl-D-aspartate Receptor or Dopamine-2 Receptor in Human Serum
10:19

High-throughput Flow Cytometry Cell-based Assay to Detect Antibodies to N-Methyl-D-aspartate Receptor or Dopamine-2 Receptor in Human Serum

Published on: November 23, 2013

16.4K
Hippocampal Neuronal Cultures to Detect and Study New Pathogenic Antibodies Involved in Autoimmune Encephalitis
08:20

Hippocampal Neuronal Cultures to Detect and Study New Pathogenic Antibodies Involved in Autoimmune Encephalitis

Published on: June 2, 2022

3.3K

Area of Science:

  • Neurology
  • Immunology

Background:

  • Antibody-mediated encephalitis (AE) requires prompt treatment for optimal outcomes.
  • Current treatment strategies for AE, including antiseizure and antipsychotic medications, are debated.
  • Standardized treatment protocols are lacking, particularly for severe or refractory AE cases.

Purpose of the Study:

  • To review and contrast the primary treatment modalities for antibody-mediated encephalitis.
  • To highlight the significance of antiseizure therapy, antipsychotic therapy, and immunotherapy/tumor resection in managing AE.
  • To underscore the need for updated guidelines and standardized procedures in AE management.

Main Methods:

  • Literature review of current treatment options for antibody-mediated encephalitis.
  • Comparative analysis of antiseizure, antipsychotic, and immunotherapy/tumor resection strategies.
  • Discussion of evidence and expert opinion on AE management.

Main Results:

  • Early immunotherapy initiation significantly impacts AE disease course.
  • The roles of antiseizure and antipsychotic therapies in AE are controversial but warrant standardized approaches.
  • Immunotherapy and tumor resection remain critical interventions for AE.

Conclusions:

  • Standardized treatment protocols are essential for antibody-mediated encephalitis, particularly for severe presentations.
  • Further research and guidelines are needed for managing refractory AE.
  • A multi-modal approach combining immunotherapy, antiseizure, and antipsychotic therapies is key to improving AE patient outcomes.